Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

10 Biggest Price Target Changes For Monday ↗

November 22, 2021

MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...

Via Benzinga

Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day

November 19, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan ↗

November 18, 2021

Novo Nordisk is buying an RNA interference company.

Via Investor's Business Daily

Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021

November 13, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Virtual R&D Day

November 12, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension

November 08, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

November 05, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Named a Science Magazine Top Employer for Third Consecutive Year

November 01, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Where Alnylam Pharmaceuticals Stands With Analysts ↗

November 01, 2021

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra...

Via Benzinga

Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript ↗

October 29, 2021

ALNY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Why Alnylam Pharmaceuticals Stock Is Tanking This Week ↗

October 29, 2021

The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.

Via The Motley Fool

Why Alnylam Pharmaceuticals Is Crashing Today ↗

October 28, 2021

The company's earnings fell short of expectations and its CEO is leaving.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 28, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

66 Biggest Movers From Yesterday ↗

October 29, 2021

Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...

Via Benzinga

Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit ↗

October 28, 2021

Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit.

Via Investor's Business Daily

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

October 28, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Planned CEO Leadership Transition

October 28, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

October 27, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results

October 14, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

3 Growth Stocks Near 52-Week Highs to Buy Anyway ↗

October 14, 2021

These top performers have what it takes to keep providing outsized gains for patient investors.

Via The Motley Fool

Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities

October 13, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 12, 2021

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

10 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

October 08, 2021

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option...

Via Benzinga

Analyst Ratings For Alnylam Pharmaceuticals ↗

October 04, 2021

Over the past 3 months, 7 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society

September 29, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference

September 28, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.